



world's first low-cost  
AI powered app & stethoscope  
for lungs





# Hello,

We're so excited to develop and present a solution to a major crisis affecting us all.

This deck provides a brief overview of the benefits LungPass can bring to every family - but especially to those with young children and the elderly.

Please don't hesitate to reach out with any question or if you want to discuss this opportunity in depth.

**Helena Binetskaya**

Healthy Networks OÜ CEO

# Respiratory

**2nd leading cause** of A&E visits and admissions



Pneumonia — 1st infectious cause of death among children, taking 850 000 lives each year



COPD — the only leading cause of death on the rise

## diagnosis is often late

---



over 40% of pneumonia cases missed at first presentation to a GP

up to 70% of COPD exacerbations reported late by patients

Current diagnostic tools lack either  
precision

---



Current diagnostic tools lack either  
precision or access

---



Current diagnostic tools lack either  
precision or access

yet continue to  
grow as demand  
surges



**€1.4B**

9% CAGR





What if  
accurate early detection system  
became massively available  
at primary care and community level?



- At least 45% of URI visits could be avoided or handled remotely

- At least 45% of URI visits could be avoided or handled remotely

And with timely treatment...

- Reduction in all-cause mortality due to pneumonia
- Up to 30% of COPD hospitalisations prevented

LungPass — distinct  
improvement in lung disease  
management

# Bluetooth stethoscope + AI powered app



Extremely affordable -  
70 euro end-user price

# Bluetooth stethoscope + AI powered app



Extremely affordable -  
70 euro end-user price

Popular with young mothers,  
used at home to mirror GP exam

# Bluetooth stethoscope + AI powered app



Extremely affordable -  
70 euro end-user price

Popular with young mothers,  
used at home to mirror GP exam

AI analysis of chest sounds -  
objective predictors of lung disease



# Bluetooth stethoscope + AI powered app



Extremely affordable -  
70 euro end-user price

Popular with young mothers,  
used at home to mirror GP exam

AI analysis of chest sounds -  
objective predictors of lung disease

94% find it easy to handle

## Now

GP: “ALRI, stay at home,  
watch out for red flags”

Day 1

Day 3

Day 5

## Now

GP: “ALRI, stay at home,  
watch out for red flags”

Symptoms worsen slightly.  
Observation continues at home  
until a noticeable deterioration

Day 1

Day 3

Day 5

## Now

GP: "ALRI, stay at home, watch out for red flags"

Symptoms worsen slightly.  
Observation continues at home until a noticeable deterioration



Day 1

Day 3

Day 5

## Now

GP: "ALRI, stay at home, watch out for red flags"

Symptoms worsen slightly.  
Observation continues at home  
until a noticeable deterioration



Day 1

Day 3

Day 5

## With LungPass

Crackles are detected.  
GP orders X-Ray >>  
confirms pneumonia

## Now

GP: "ALRI, stay at home, watch out for red flags"

Symptoms worsen slightly.  
Observation continues at home  
until a noticeable deterioration



Day 1

Day 3

Day 5

## With LungPass

Crackles are detected.  
GP orders X-Ray >>  
confirms pneumonia





# LungPass accuracy

in comparison with a panel of pulmonologists


	Accuracy	Sensitivity	Specificity
Normal	95.50%	96.88%	90.00%
Crackles	90.50%	92.50%	82.50%
Wheezes	97.50%	99.38%	90.00%
Artifacts	98.00%	98.75%	95.00%
Heart sounds	94.50%	97.50%	82.50%

# LungPass performance in pneumonia

'Regular' pneumonia, 148 patients

95% - LungPass revealed crackles,  
incl. cases with mild or unclear symptoms

---




# LungPass performance in pneumonia

'Regular' pneumonia, 148 patients

95% - LungPass revealed crackles,  
incl. cases with mild or unclear symptoms

---



COVID-19, 61 patients

88.5% - LungPass revealed crackles v. 31% by GP

Control group, 90 records taken:  
89 – normal breathing (true), 1 crackles (false)



# LungPass performance in COPD

30 self monitoring patient cohort

Change in sound pattern 7+ days prior to hospitalisation



# Commercialisation



Direct  
sales



Retail price

€70

# Commercialisation



Direct  
sales

⋮

Retail price

€70




Value-based  
procurement

DVG

Price determined by a tender scope



# Action plan





# Our mission — reduce global respiratory burden

by making early lung disease detection  
available to everyone

Join us in bringing  
LungPass  
to every home!



Helena Binetskaya, CEO and co-founder,  
helena@lungpass.com

add me on LinkedIN: